Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas

Clinical Cancer Research

Volumn 22, Issue 9, 2016, Pages 2290-2300

  Morin, Ryan D ^a,b   Assouline, Sarit ^b,c   Alcaide, Miguel ^a   Mohajeri, Arezoo ^a   Johnston, Rebecca L ^d   Chong, Lauren ^d   Grewal, Jasleen ^a   Yu, Stephen ^a   Fornika, Daniel ^a   Bushell, Kevin ^a   Nielsen, Torsten Holm ^e   Petrogiannis Haliotis, Tina ^f   Crump, Michael ^e   Tosikyan, Axel ^c   Grande, Bruno M ^a   MacDonald, David ^g   Rousseau, Caroline ^h   Bayat, Maryam ^c   Sesques, Pierre ^b   Froment, Remi ^b   Albuquerque, Marco ^a   Monczak, Yury ^f   Oros, Kathleen Klein ⁱ   Greenwood, Celia ^d,i   Riazalhosseini, Yasser ^j   Arseneault, Madeleine ^j   Camlioglu, Errol ^c   Constantin, Andre ^c   Qiang, Pan Hammarstrom ^k,l   Peng, Roujun ^k,l   Mann, Koren K ^b,c   Johnson, Nathalie A ^b,c   more..

^a SIMON FRASER UNIVERSITY   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e McGill University ^*  (Denmark)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g DALHOUSIE UNIVERSITY   (Canada)

^h PRINCESS MARGARET HOSPITAL   (Canada)

ⁱ MCGILL UNIVERSITY   (Canada)

^j MCGILL UNIVERSITY   (Canada)

^k KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^l SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD79B ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; MYELOID DIFFERENTIATION FACTOR 88; PREDNISONE; PROTEIN P53; RITUXIMAB; STAT PROTEIN; STAT6 PROTEIN; TRANSCRIPTION FACTOR FKHR; VINCRISTINE; CD79 ANTIGEN; CYCLIN D3; MIXED LINEAGE LEUKEMIA PROTEIN; NUCLEAR PROTEIN;

ARTICLE; B LYMPHOCYTE; CANCER RECURRENCE; CCND3 GENE; CD79B GENE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; FOXO1 GENE; GENE; GENE MUTATION; GERMINAL CENTER; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; MLL3 GENE; MYD88 GENE; NFKBIE GENE; NFKBIZ GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELAPSED AND REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA; SIGNAL TRANSDUCTION; STAT6 GENE; TP53 GENE; ADULT; AGED; DIFFUSE LARGE B CELL LYMPHOMA; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; MIDDLE AGED; MUTATION; PROSPECTIVE STUDY; TUMOR RECURRENCE;

ADULT; AGED; B-LYMPHOCYTES; CD79 ANTIGENS; CYCLIN D3; FEMALE; FORKHEAD BOX PROTEIN O1; GENE EXPRESSION REGULATION, NEOPLASTIC; GERMINAL CENTER; HUMANS; JANUS KINASES; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MUTATION; MYELOID DIFFERENTIATION FACTOR 88; MYELOID-LYMPHOID LEUKEMIA PROTEIN; NEOPLASM RECURRENCE, LOCAL; NF-KAPPA B; NUCLEAR PROTEINS; PROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; STAT6 TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84968817466     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-2123     Document Type: Article

References (49)

1. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42.
2. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-11.
3. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008;359:2313-23.
4. Kuruvilla J, MacDonald DA, Kouroukis CT, Cheung M, Olney HJ, Turner AR, et al. Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12. Blood 2015;126:733-8.
5. Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011;476:298-303.
6. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010;42:181-5.
7. Morin RD, Mungall K, Pleasance E, Mungall AJ, Goya R, Huff RD, et al. Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. Blood 2013;122:1256-65.
8. Pasqualucci L, Trifonov V, Fabbri G, Ma J, Rossi D, Chiarenza A, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 2011;43:830-7.
9. Zhang J, Grubor V, Love CL, Banerjee A, Richards KL, Mieczkowski PA, et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A 2013;110:1398-403.
10. Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, Sougnez C, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A 2012;109:3879-84.
11. Challa-Malladi M, Lieu YK, Califano O, Holmes AB, Bhagat G, Murty VV, et al. Combined genetic inactivation of beta2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell 2011;20:728-40.
12. Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011;471:189-95.
13. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010;463:88-92.
14. Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008;319:1676-9.
15. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011; 470:115-9.
16. Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009;459:717-21.
17. Pasqualucci L, Khiabanian H, Fangazio M, Vasishtha M, Messina M, Holmes AB, et al. Genetics of follicular lymphoma transformation. Cell Reps 2014;6:130-40.
18. Okosun J, Bodor C, Wang J, Araf S, Yang CY, Pan C, et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet 2014;46:176-81.
19. Jiang Y, Redmond D, Nie K, Eng KW, Clozel T, Martin P, et al. Deep sequencing reveals clonal evolution patterns and mutation events associated with relapse in B-cell lymphomas. Genome Biol 2014;15:432.
20. de Miranda NF, Georgiou K, Chen L, Wu C, Gao Z, Zaravinos A, et al. Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese patients. Blood 2014;124:2544-53.
21. Ritz O, Guiter C, Castellano F, Dorsch K, Melzner J, Jais JP, et al. Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma. Blood 2009;114:1236-42.
22. Yildiz M, Li H, Bernard D, Amin NA, Ouillette P, Jones S, et al. Activating STAT6 mutations in follicular lymphoma. Blood 2015;125:668-79.
23. Ritz O, Rommel K, Dorsch K, Kelsch E, Melzner J, Buck M, et al. STAT6-mediated BCL6 repression in primary mediastinal B-cell lymphoma (PMBL). Oncotarget 2013;4:1093-102.
24. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri S, Stein H, et al., WHO Classification of tumours of haematopoietic and lymphoid tissues: IARC: Lyon, France; 2008.
25. Nielsen TH, Diaz Z, Christodoulopoulos R, Charbonneau F, Qureshi S, Rousseau C, et al. Methods for sample acquisition and processing of serial blood and tumor biopsies for multicenter diffuse large B-cell lymphoma clinical trials. Cancer Epidemiol Biomarkers Prev 2014;23:2688-93.
26. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-82.
27. Saunders CT, Wong WS, Swamy S, Becq J, Murray LJ, Cheetham RK. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics 2012;28:1811-7.
28. Ha G, Roth A, Khattra J, Ho J, Yap D, Prentice LM, et al. TITAN: inference of copy number architectures in clonal cell populations from tumor wholegenome sequence data. Genome Res 2014;24:1881-93.
29. Trinh DL, Scott DW, Morin RD, Mendez-Lago M, An J, Jones SJ, et al. Analysis of FOXO1 mutations in diffuse large B-cell lymphoma. Blood 2013;121:3666-74.
30. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 2003;100:9991-6.
31. Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 2012;490:116-20.
32. Bahram F, von der Lehr N, Cetinkaya C, Larsson LG. c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood 2000;95:2104-10.
33. Li Z, Nabel GJ. A new member of the I kappaB protein family, I kappaB epsilon, inhibits RelA (p65)-mediated NF-kappaB transcription. Mol Cell Biol 1997;17:6184-90.
34. Alves BN, Tsui R, Almaden J, Shokhirev MN, Davis-Turak J, Fujimoto J, et al. IkappaBepsilon is a key regulator of B cell expansion by providing negative feedback on cRel and RelA in a stimulus-specific manner. J Immunol 2014;192:3121-32.
35. Emmerich F, Theurich S, Hummel M, Haeffker A, Vry MS, Dohner K, et al. Inactivating I kappa B epsilon mutations in Hodgkin/Reed-Sternberg cells. J Pathol 2003;201:413-20.
36. Domenech E, Gomez-Lopez G, Gzlez-Pena D, Lopez M, Herreros B, Menezes J, et al. New mutations in chronic lymphocytic leukemia identified by target enrichment and deep sequencing. PLoS One 2012;7: e38158.
37. Mansouri L, Sutton LA, Ljungstrom V, Bondza S, Arngarden L, Bhoi S, et al. Functional loss of IkappaBepsilon leads to NF-kappaB deregulation in aggressive chronic lymphocytic leukemia. J Exp Med 2015;212:833-43.
38. Nogai H, Wenzel SS, Hailfinger S,GrauM, KaergelE, SeitzV, etal. IkappaBzeta controls the constitutive NF-kappaB target gene network and survival of ABC DLBCL. Blood 2013;122:2242-50.
39. Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 2015;21:922-6.
40. Dunleavy K, Pittaluga S, Czuczman MS, Dave SS, Wright G, Grant N, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 2009;113:6069-76.
41. Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, Pileri SA, Malik F, Macon WR, et al. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer 2011;117:5058-66.
42. Thieblemont C, Briere J, Mounier N, Voelker HU, Cuccuini W, Hirchaud E, et al. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol 2011;29:4079-87.
43. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012;492:108-12.
44. Xu-Monette ZY, Wu L, Visco C, Tai YC, Tzankov A, Liu WM, et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood 2012;120:3986-96.
45. Malina A, Mills JR, Cencic R, Yan Y, Fraser J, Schippers LM, et al. Repurposing CRISPR/Cas9 for in situ functional assays. Genes Dev 2013;27:2602-14.
46. Skinnider BF, Elia AJ, Gascoyne RD, Patterson B, Trumper L, Kapp U, et al. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 2002;99:618-26.
47. Ritz O, Guiter C, Dorsch K, Dusanter-Fourt I, Wegener S, Jouault H, et al. STAT6 activity is regulated by SOCS-1 and modulates BCL-XL expression in primary mediastinal B-cell lymphoma. Leukemia 2008;22: 2106-10.
48. Ok CY, Chen J, Xu-Monette ZY, Tzankov A, Manyam GC, Li L, et al. Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma. Clin Cancer Res 2014;20:5113-23.
49. Schif B, Lennerz JK, Kohler CW, Bentink S, Kreuz M, Melzner I, et al. SOCS1 mutation subtypes predict divergent outcomes in diffuse large B-cell lymphoma (DLBCL) patients. Oncotarget 2013;4:35-47.